Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
2018;67:S175S84
639 Despite early study termination (clinical hold) by the US Food and Drug Administration, fulranumab treatment resulted in dose-dependent efficacy and was generally well tolerated
The decision framework proposed here integrates biological plausibility, translational evidence, safety signals, and technological feasibility
Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics
US$ 25.76
US$ 26.24
US$ 21.45
US$ 24.18
US$ 25.77
US$ 22.73
